Cardiac toxicity of ErbB2-targeted therapies: what do we know? [electronic resource]
Producer: 20080930Description: S114-20 p. digitalISSN:- 1526-8209
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Clinical Trials as Topic
- Female
- Heart -- drug effects
- Heart Failure -- chemically induced
- Humans
- Lapatinib
- Quinazolines -- adverse effects
- Receptor, ErbB-2 -- antagonists & inhibitors
- Trastuzumab
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.